Aditxt Inc. (NASDAQ: ADTX), through its subsidiary Pearsanta, Inc., has reached a pivotal milestone in the development of a novel diagnostic tool for ovarian cancer. The U.S. Department of Defense's OCRP Pilot Award has invited Pearsanta to submit a full proposal for funding, following a favorable review of its pre-proposal. The Mitomic(R) Ovarian Test (MOT(TM)) represents a breakthrough in early detection, utilizing a blood-based approach to identify ovarian cancer at its nascent stages.
The potential grant of up to $350,000 over two years would enable Pearsanta to validate the MOT(TM) through a multi-center clinical study and prepare for its commercial launch as a laboratory-developed test. This development is crucial given the high mortality rate associated with ovarian cancer, often due to late detection. Early diagnosis could significantly improve patient outcomes, reducing the burden of this disease on individuals and the healthcare system.
Aditxt's innovative platform, which fosters collaboration among research institutions, industry partners, and shareholders, underscores the importance of this achievement. The company's focus on precision health, through programs like Pearsanta's MOT(TM), exemplifies its commitment to addressing urgent health challenges with cutting-edge solutions. For more information on Aditxt's initiatives, visit https://www.Aditxt.com.
